menu
    • menu
    [{"orgOrder":0,"company":"Philip Morris International","sponsor":"Philip Morris International","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"Aspirin","moa":"Cyclooxygenase","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Philip Morris International","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Powder for Inhalation","sponsorNew":"Philip Morris International \/ Philip Morris International","highestDevelopmentStatusID":"1","companyTruncated":"Philip Morris International \/ Philip Morris International"},{"orgOrder":0,"company":"Philip Morris International","sponsor":"Fertin Pharma AS","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"DENMARK","productType":"Controlled Substance","year":"2021","type":"Acquisition","leadProduct":"Nicotine","moa":"Neuronal acetylcholine receptor; alpha4\/beta2","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Philip Morris International","amount2":0.81999999999999995,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0.81999999999999995,"dosageForm":"Oral Gum, Chewing","sponsorNew":"Philip Morris International \/ Philip Morris International","highestDevelopmentStatusID":"6","companyTruncated":"Philip Morris International \/ Philip Morris International"},{"orgOrder":0,"company":"Philip Morris International","sponsor":"Fertin Pharma AS","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"DENMARK","productType":"Controlled Substance","year":"2021","type":"Acquisition","leadProduct":"Nicotine","moa":"Neuronal acetylcholine receptor; alpha4\/beta2","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Philip Morris International","amount2":0.81999999999999995,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0.81999999999999995,"dosageForm":"Oral Gum, Chewing","sponsorNew":"Philip Morris International \/ Philip Morris International","highestDevelopmentStatusID":"6","companyTruncated":"Philip Morris International \/ Philip Morris International"}]

    Find Clinical Drug Pipeline Developments & Deals by Philip Morris International

    Menu

    Philip Morris International

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Philip Morris International

                            Switzerland arrow
                            Peptide Process CMC
                            Not Confirmed

                            Philip Morris International

                            Switzerland arrow
                            Peptide Process CMC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nicotine

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Undisclosed

                            Recipient : Fertin Pharma AS

                            Deal Size : $820.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Philip Morris International Announces Closing of Fertin Pharma Acquisition; Advances PMI’s Goal of Becoming ...

                            Details : Through the acquisition, PMI will build its overall platform of R&D and manufacturing expertise in nicotine and beyond nicotine product areas through the addition of Fertin’s strong capabilities and skilled workforce.

                            Product Name : Undisclosed

                            Product Type : Controlled Substance

                            Upfront Cash : Undisclosed

                            September 15, 2021

                            Lead Product(s) : Nicotine

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Undisclosed

                            Recipient : Fertin Pharma AS

                            Deal Size : $820.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Philip Morris International

                            Switzerland arrow
                            Peptide Process CMC
                            Not Confirmed

                            Philip Morris International

                            Switzerland arrow
                            Peptide Process CMC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Aspirin

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Undisclosed

                            Recipient : OtiTopic

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Philip Morris International Acquires Inhaled Drug Specialist OtiTopic

                            Details : OtiTopic develops the Asprihale patented dry powder inhalation ASA treatment to treat acute myocardial infarction as a self-administered aerosol. The company expects to move from clinical trials of Asprihale to filing for FDA approval at some point in 20...

                            Product Name : Asprihale

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            September 08, 2021

                            Lead Product(s) : Aspirin

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Undisclosed

                            Recipient : OtiTopic

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Philip Morris International

                            Switzerland arrow
                            Peptide Process CMC
                            Not Confirmed

                            Philip Morris International

                            Switzerland arrow
                            Peptide Process CMC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nicotine

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Undisclosed

                            Recipient : Fertin Pharma AS

                            Deal Size : $820.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Philip Morris International Announces Agreement to Acquire Fertin Pharma

                            Details : Through the acquisition, PMI will build its overall platform of R&D and manufacturing expertise in nicotine and beyond nicotine product areas through the addition of Fertin’s strong capabilities and skilled workforce.

                            Product Name : Undisclosed

                            Product Type : Controlled Substance

                            Upfront Cash : Undisclosed

                            January 07, 2021

                            Lead Product(s) : Nicotine

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Undisclosed

                            Recipient : Fertin Pharma AS

                            Deal Size : $820.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth